Cvfg LLC Acquires 18,261 Shares of AbbVie Inc. $ABBV

Cvfg LLC increased its holdings in AbbVie Inc. (NYSE:ABBV) by 1,304.4% in the first quarter, Holdings Channel reports. The institutional investor owned 19,661 shares of the company’s stock after buying an additional 18,261 shares during the period. Cvfg LLC’s holdings in AbbVie were worth $4,276,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in ABBV. Norges Bank acquired a new stake in AbbVie during the fourth quarter worth about $5,865,055,000. Wellington Management Group LLP raised its position in shares of AbbVie by 457.4% in the 3rd quarter. Wellington Management Group LLP now owns 10,536,901 shares of the company’s stock valued at $2,439,714,000 after buying an additional 8,646,424 shares in the last quarter. Capital World Investors lifted its holdings in shares of AbbVie by 106.3% during the 4th quarter. Capital World Investors now owns 13,071,444 shares of the company’s stock worth $2,986,777,000 after acquiring an additional 6,736,161 shares during the period. Cardano Risk Management B.V. lifted its holdings in shares of AbbVie by 914.6% during the 4th quarter. Cardano Risk Management B.V. now owns 5,444,930 shares of the company’s stock worth $1,244,112,000 after acquiring an additional 4,908,260 shares during the period. Finally, Geode Capital Management LLC increased its stake in AbbVie by 10.4% in the fourth quarter. Geode Capital Management LLC now owns 44,629,980 shares of the company’s stock valued at $10,179,099,000 after acquiring an additional 4,190,487 shares during the last quarter. Institutional investors and hedge funds own 70.23% of the company’s stock.

AbbVie Stock Performance

Shares of ABBV opened at $254.71 on Wednesday. AbbVie Inc. has a 52 week low of $184.63 and a 52 week high of $261.64. The stock has a market capitalization of $450.02 billion, a price-to-earnings ratio of 125.47, a PEG ratio of 0.84 and a beta of 0.30. The stock has a fifty day moving average of $222.39 and a 200-day moving average of $220.69.

AbbVie (NYSE:ABBV) last issued its earnings results on Wednesday, April 29th. The company reported $2.65 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.59 by $0.06. The business had revenue of $15 billion during the quarter, compared to analysts’ expectations of $14.72 billion. AbbVie had a negative return on equity of 576.45% and a net margin of 5.79%.The business’s revenue for the quarter was up 12.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.46 EPS. As a group, equities analysts forecast that AbbVie Inc. will post 14.28 EPS for the current year.

AbbVie Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, August 14th. Stockholders of record on Wednesday, July 15th will be paid a $1.73 dividend. The ex-dividend date of this dividend is Wednesday, July 15th. This represents a $6.92 annualized dividend and a dividend yield of 2.7%. AbbVie’s dividend payout ratio is currently 340.89%.

Analysts Set New Price Targets

Several research analysts have commented on the stock. Weiss Ratings restated a “hold (c)” rating on shares of AbbVie in a research report on Monday, June 8th. Guggenheim reaffirmed a “buy” rating and issued a $249.00 target price on shares of AbbVie in a report on Friday, May 1st. Cantor Fitzgerald lifted their price target on AbbVie from $240.00 to $265.00 and gave the company an “overweight” rating in a research note on Monday. DZ Bank upgraded AbbVie from a “hold” rating to a “strong-buy” rating in a research report on Thursday, April 30th. Finally, Sanford C. Bernstein reaffirmed a “market perform” rating on shares of AbbVie in a research note on Tuesday, June 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $256.67.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: The European Commission approved TEPKINLY (epcoritamab) plus lenalidomide and rituximab for relapsed or refractory follicular lymphoma, making it the first and only bispecific-based therapy approved in Europe for this setting and expanding AbbVie’s oncology growth opportunity. Article Title
• Positive Sentiment: Cantor Fitzgerald raised its price target on AbbVie to $265 from $240 and reiterated an overweight rating, signaling continued analyst confidence in the stock’s outlook. Article Title
• Neutral Sentiment: Media coverage highlighted AbbVie as a high-yield dividend and “quality, low-stress” healthcare stock, which may support investor sentiment but does not change fundamentals. Article Title
• Negative Sentiment: AbbVie lowered its Q2 2026 EPS guidance to $3.57-$3.61 versus the consensus $3.77, suggesting earnings could come in below expectations. Article Title
• Negative Sentiment: The company also cut full-year 2026 EPS guidance to $13.91-$14.11, below the consensus estimate of $14.25, which may pressure the shares despite recent product wins. Article Title

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.